Last reviewed · How we verify
Active Comparator: FOLFOX plus cetuximab
FOLFOX plus cetuximab combines chemotherapy with an EGFR-targeting monoclonal antibody to kill colorectal cancer cells through dual mechanisms of DNA damage and growth factor receptor inhibition.
FOLFOX plus cetuximab combines chemotherapy with an EGFR-targeting monoclonal antibody to kill colorectal cancer cells through dual mechanisms of DNA damage and growth factor receptor inhibition. Used for Metastatic colorectal cancer, KRAS wild-type, Locally advanced colorectal cancer.
At a glance
| Generic name | Active Comparator: FOLFOX plus cetuximab |
|---|---|
| Sponsor | Chinese Academy of Medical Sciences |
| Drug class | Chemotherapy regimen plus monoclonal antibody |
| Target | EGFR (cetuximab component); DNA (FOLFOX component) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
FOLFOX is a chemotherapy regimen (fluorouracil, leucovorin, and oxaliplatin) that damages DNA and inhibits cell division. Cetuximab is a monoclonal antibody that binds to epidermal growth factor receptor (EGFR) on cancer cells, blocking growth signaling and enhancing immune-mediated cell death. Together, they provide synergistic anti-tumor activity in EGFR-expressing colorectal cancers.
Approved indications
- Metastatic colorectal cancer, KRAS wild-type
- Locally advanced colorectal cancer
Common side effects
- Neutropenia
- Diarrhea
- Nausea/vomiting
- Peripheral neuropathy
- Acneiform rash
- Anemia
- Fatigue
Key clinical trials
- Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer (PHASE3)
- The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: